Enicepatide
Lilly's oral GLP-1 Foundayo (orforglipron) delivered superior A1C control and weight loss in three pivotal type 2 diabetes trials
Pressure score
64
Momentum score
20
Why This Matters
Lilly is a direct competitive threat because it has a Phase III program in Endocrinology · GLP-1/GIP Agonist (Enicepatide) and could narrow Roche's development lead.
Competitive Assessment
- Threat type
- direct competitor
- Development stage
- Phase III
- Stage gap
- Stage comparison unavailable — competitor development phase not fully evidenced.
- Market share risk
- Late-stage competitor could compress launch window and payer leverage before approval.
Strategic Action
Align with signal posture: monitor. Monitor direct competitor activity and refresh competitive intelligence after material readouts.
Overlap Analysis
Source Analysis
Lilly's oral GLP-1 Foundayo (orforglipron) delivered superior A1C control and weight loss in three pivotal type 2 diabetes trials
Lilly's Enicepatide directly references the same indication focus (Endocrinology · GLP-1/GIP Agonist) as this signal.
Source: Lilly
View source documentRelated Signal
Hoffmann-La Roche's Enicepatide Trial Targets Obesity and Type 2 Diabetes
Open signalCompetitor Position
Competitor race
Pressure ranking for this signal's competitive set
Position: #1 of 2
Lilly
2 competitive findings
Top program: Enicepatide
- Pressure
- 64
- Momentum
- 20
- Threat
- direct competitor
- Stage
- Phase III
64LillyMediumEnicepatide·Phase III
Pfizer
1 competitive finding
Top program: Enicepatide
- Pressure
- 51
- Momentum
- 5
- Threat
- direct competitor
- Stage
- Stage unknown
51PfizerMediumEnicepatide·Stage unknown